IMW 2026: vídeos e entrevistas

172 vídeos do IMW 2026 publicados por Targeted Oncology, VJHemOnc. Atualizado em 20/11/2026.

Ver no OncoTV com filtros

How may exercise and orthopedic care support bone health in patients with myeloma from diagnosis?VJHemOnc · 10/11/2026 · 2:37 · apoio da indústriaHow may serial sampling of cfDNA track disease dynamics and detect early progression in myeloma?VJHemOnc · 10/11/2026 · 1:37 · apoio da indústriaPrognostic value of using NGF to identify aberrant plasma cell subtypes in newly diagnosed myelomaVJHemOnc · 10/11/2026 · 1:46 · apoio da indústriaUpdate from DART4MM: daratumumab consolidation after ASCT in patients with multiple myelomaVJHemOnc · 10/11/2026 · 2:30 · apoio da indústriaIdentifying racial and socioeconomic disparities in second primary malignancy onset in myelomaVJHemOnc · 10/11/2026 · 1:37 · apoio da indústriaInsights into a SEER analysis of non-cancer mortality trends in multiple myelomaVJHemOnc · 10/11/2026 · 1:42 · apoio da indústriaChoosing between imaging modalities in multiple myeloma: advice for physiciansVJHemOnc · 10/11/2026 · 1:57 · apoio da indústriaInsights into premedication and infusion-related reactions with subcutaneous isatuximab in myelomaVJHemOnc · 10/11/2026 · 1:40 · apoio da indústriaAI-designed BCMA/FcRL5 targeting trispecific antibody to overcome antigen escape in multiple myelomaVJHemOnc · 06/11/2026 · 2:40 · apoio da indústriaOutpatient ramantamig administration in myeloma: managing CRS and neurotoxicityVJHemOnc · 03/11/2026 · 2:19 · apoio da indústriaManaging dose interruptions and re-treatment with T-cell engagers in myelomaVJHemOnc · 03/11/2026 · 1:18 · apoio da indústriaRamantamig and dual-antigen targeting in relapsed/refractory myelomaVJHemOnc · 03/11/2026 · 1:20 · apoio da indústriaDiscussing the concept of a cure in multiple myeloma: is the term over-promising?VJHemOnc · 03/11/2026 · 3:01 · apoio da indústriaWhole-body MRI and progression risk in smoldering myelomaVJHemOnc · 03/11/2026 · 2:10 · apoio da indústriaPeripheral neuropathy in smoldering myelomaVJHemOnc · 03/11/2026 · 2:04 · apoio da indústriaMacrophage reprogramming and response to PD-1 blockade in smoldering myelomaVJHemOnc · 03/11/2026 · 1:25 · apoio da indústriaCAR T-cell therapy versus bispecific antibodies in high-risk smoldering myelomaVJHemOnc · 03/11/2026 · 1:10 · apoio da indústriaManaging CNS-involved myeloma: CAR T-cell access and alternative treatment strategiesVJHemOnc · 03/11/2026 · 1:11 · apoio da indústriaAnti-BCMA CAR T-cell therapy in CNS-involved myeloma: safety and long-term outcomesVJHemOnc · 03/11/2026 · 3:49 · apoio da indústriaDREAMM-9: extended belantamab dosing and vision-related outcomes in myelomaVJHemOnc · 03/11/2026 · 6:09 · apoio da indústriaGenomic risk stratification and treatment consistency in myelomaVJHemOnc · 03/11/2026 · 1:24 · apoio da indústriaThe role of CELMoDs in relapsed myelomaVJHemOnc · 03/11/2026 · 1:17 · apoio da indústriaImplementing MRD-guided treatment in community myeloma careVJHemOnc · 03/11/2026 · 2:18 · apoio da indústriaGEM-TECTAL: MRD-guided T-cell redirection in high-risk myelomaVJHemOnc · 03/11/2026 · 2:29 · apoio da indústriaLENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytomaVJHemOnc · 03/11/2026 · 3:31 · apoio da indústriaThe association between high blood sugar and CAR-T outcomes in multiple myelomaVJHemOnc · 03/11/2026 · 5:58 · apoio da indústriaReal-world outcomes of DVd in myeloma at first relapse and its role in the evolving landscapeVJHemOnc · 03/11/2026 · 1:21 · apoio da indústriaMRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAINVJHemOnc · 02/11/2026 · 2:51 · apoio da indústriaInfection-related mortality in myeloma: trends, disparities and prevention strategiesVJHemOnc · 02/11/2026 · 1:59 · apoio da indústriaSelf-administration of bortezomib in myeloma and amyloidosis: feasibility study findingsVJHemOnc · 02/11/2026 · 3:29 · apoio da indústriaPhase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myelomaVJHemOnc · 02/11/2026 · 3:16 · apoio da indústriaCilta-cel in earlier-line myeloma: insights into updated survival dataVJHemOnc · 29/10/2026 · 1:17 · apoio da indústriaASCO Living Guideline updates in multiple myeloma: CAR T-cell therapy versus bispecific antibodiesVJHemOnc · 29/10/2026 · 3:15 · apoio da indústriaCAR T-cell therapy in R/R myeloma: adverse-event management costs and treatment selectionVJHemOnc · 29/10/2026 · 2:44 · apoio da indústriaIdentifying patients who need curative treatment versus disease control in myelomaVJHemOnc · 29/10/2026 · 3:46 · apoio da indústriaThe future of AI in hematology: personalized medicine, opportunities and risksVJHemOnc · 29/10/2026 · 2:30 · apoio da indústriaThe ethical challenges of AI in hematology: patient communication, trust and regulationVJHemOnc · 29/10/2026 · 3:12 · apoio da indústriaAdvances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodiesVJHemOnc · 29/10/2026 · 4:55 · apoio da indústriaThe role of patient preference in selecting treatment administration routes in multiple myelomaVJHemOnc · 29/10/2026 · 1:35 · apoio da indústriaPatient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCOVJHemOnc · 29/10/2026 · 2:02 · apoio da indústriaOn-body injector delivery of subcutaneous isatuximab in multiple myelomaVJHemOnc · 27/10/2026 · 1:38 · apoio da indústriaEx vivo drug sensitivity profiling to guide treatment selection in R/R multiple myelomaVJHemOnc · 27/10/2026 · 1:47 · apoio da indústriaAddressing access challenges to bispecifics for patients with multiple myeloma in Asian countriesVJHemOnc · 21/10/2026 · 2:06 · apoio da indústriaMulti-omics reveals a molecular signature in TP53-mutated myeloma: insights & clinical implicationsVJHemOnc · 21/10/2026 · 2:42 · apoio da indústriaKey updates on newly diagnosed multiple myeloma: progress and challenges in high-risk diseaseVJHemOnc · 21/10/2026 · 2:34 · apoio da indústriaExploring arginine metabolism and ASS1 status in t(11;14) myelomaVJHemOnc · 21/10/2026 · 4:24 · apoio da indústriaPre-treatment genomic screening to guide venetoclax-based sequencing in t(11;14) myelomaVJHemOnc · 21/10/2026 · 1:09 · apoio da indústriaThe potential benefits of fixed-duration bispecific antibody therapy in multiple myelomaVJHemOnc · 16/10/2026 · 1:22 · apoio da indústriaCAMMA 1: fixed-duration cevostamab shows durable responses in R/R multiple myelomaVJHemOnc · 16/10/2026 · 6:22 · apoio da indústriaIndividualized bridging therapy before BCMA-directed CAR T-cell therapyVJHemOnc · 15/10/2026 · 1:17 · apoio da indústriaHypogammaglobulinemia, infection risk, and IgG replacement therapy in myelomaVJHemOnc · 15/10/2026 · 1:46 · apoio da indústriaEfficacy and safety of GPRC5D-targeted QLS32015 in multiple myelomaVJHemOnc · 14/10/2026 · 2:49 · apoio da indústriaOutpatient administration of T-cell-redirecting antibodies in multiple myelomaVJHemOnc · 14/10/2026 · 1:28 · apoio da indústriaTRIlogy-1 trial: updated ramantamig safety and efficacy data in relapsed/refractory multiple myelomaVJHemOnc · 14/10/2026 · 1:35 · apoio da indústriaCERVINO trial results and the potential role of etentamig in multiple myelomaVJHemOnc · 14/10/2026 · 1:19 · apoio da indústriaIMS 2026 highlights: evolving multiple myeloma treatment and the path toward cureVJHemOnc · 14/10/2026 · 7:00 · apoio da indústriaImplementing bispecific antibodies in triple-class-exposed multiple myelomaVJHemOnc · 14/10/2026 · 1:46 · apoio da indústriaLong-term outcomes with KRd versus Rd in high-risk smoldering multiple myelomaVJHemOnc · 14/10/2026 · 4:22 · apoio da indústriaSupplement use in MGUS, smoldering myeloma, and multiple myeloma: findings from a patient surveyVJHemOnc · 14/10/2026 · 3:12 · apoio da indústriaNUTRIVENTION-5: a decentralized trial of a plant-based diet during induction therapy in NDMMVJHemOnc · 14/10/2026 · 4:50 · apoio da indústria